Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
Egbert F. Smit(Dutch Cancer Society), Enriqueta Felip(Vall d'Hebron Institute of Oncology), Dipesh Uprety(The Barbara Ann Karmanos Cancer Institute), Misako Nagasaka(University of California, Irvine), Kazuhiko Nakagawa(Kindai University Hospital), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Jose M. Pacheco(University of Colorado Anschutz Medical Campus), Bob T. Li(Memorial Sloan Kettering Cancer Center), David Planchard(Institut Gustave Roussy), Christina S. Baik(University of Washington Medical Center), Yasushi Goto(Tokyo National Hospital), Haruyasu Murakami(Shizuoka Cancer Center), Andreas Saltos(Moffitt Cancer Center), Kaline Pereira(Daiichi Sankyo (United States)), Ayumi Taguchi(Daiichi-Sankyo (Japan)), Yingkai Cheng(Daiichi Sankyo (United States)), Qi Yan(Daiichi Sankyo (United States)), Wenqin Feng(Daiichi Sankyo (United States)), Zenta Tsuchihashi(Daiichi Sankyo (United States)), Pasi A. Jänne(Dana-Farber Cancer Institute)
Cited by 150Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis